The identification of mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC). The effectiveness of individualized treatment using EGFR tyrosine kinase inhibitors (TKIs) for EGFRmutated NSCLC has mainly been clarified in clinical trials within Japan, and EGFR-TKI monotherapy has been established as the standard first-line treatment for EGFR-mutated NSCLC. Since then, combination regimens involving EGFR-TKI and chemotherapy or anti-angiogenic agents have been developed. Regarding combinations, the NEJ009 study conducted in Japan showed a significant prolongation of progression-free survival and overall survival compared with gefitinib alone. The NEJ009 regimen may be a reasonable option for patients with good performance status in terms of risk-benefit balance. However, further investigation is warranted to improve clinical outcomes in EGFR-mutated NSCLC.
|ジャーナル||Proceedings of the Japan Academy Series B: Physical and Biological Sciences|
|出版ステータス||Published - 2020|
ASJC Scopus subject areas